Small molecules that bind to alpha-synuclein deposition and can be used for PET imagining in patients with synucleinopathies Problem: Imaging alpha-synuclein (αS) using noninvasive techniques such as positron emission tomography (PET) can help with the early diagnosis of synucleinopathies. Previous PET radiotracers suffer from low binding affinity and off-target binding to structurally similar proteins, such as amyloid-beta (Ab) and tau. Currently, there is no clear candidate for PET imaging studies in patients with synucleinopathies. Solution: Dr. Robert Mach and his team at the Medical School of the University of Pennsylvania have identified different scaffolds that exhibit varying propertied for imaging alpha-synuclein in the brains of patients with Multiple System Atrophy (MSA) and Parkinson's Disease (PD. This is a promising development in the clinical differentiation of MSA and PD patients and the monitoring of therapeutic strategies aimed at reducing alpha synuclein burden in the synucleinopathies. Advantages:
Stage of Development:
PET radiotracers combining autoradiography enable visualizing the distribution of aggregated α-synuclein in PD and MSA tissues
Intellectual Property:
Reference Media:
Desired Partnerships:
Docket# 23-10326